News Releases

Light-activated small molecule could transform eye infection treatment

Light-activated small molecule could transform eye infection treatment

Many contact lens users occasionally fall asleep with their lenses in. However, this can cause dry and irritated eyes and blurry vision, which may be a sign of a serious infection.

Authority Magazine Interview

Authority Magazine Interview

May 7, 2025 – Authority Magazine launched a new interview series highlighting tech leaders creating meaningful social and environmental change. As part of “Technology Making An Important Positive Social Impact,” Edward Pershing, Chairman of VisiRose, Inc. and CEO of Provectus Biopharmaceuticals, was interviewed about his company’s impact.

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 – Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc., Provectus’s Founded Entity that is developing novel ocular therapeutics.

VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics

January 14, 2025 — VisiRose Inc. today announced the closing of a $3 million seed financing round.

Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

Dec 11, 2024 - Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity.

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Dec 10, 2024 - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI).

Bascom Palmer Eye Institute Ranked Nation's No. 1 in Ophthalmology for 23rd Time

Bascom Palmer Eye Institute Ranked Nation's No. 1 in Ophthalmology for 23rd Time

July 16, 2024 - For the 23rd time, Bascom Palmer Eye Institute, part of the University of Miami Health System and the University of Miami Miller School of Medicine, has been ranked the nation’s Best in Ophthalmology by U.S. News & World Report in its annual Best Hospitals survey.